Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Current Assets (2022 - 2025)

Historic Current Assets for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q3 2025 value amounting to $66.9 million.

  • Corvus Pharmaceuticals' Current Assets rose 5597.03% to $66.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.9 million, marking a year-over-year increase of 5597.03%. This contributed to the annual value of $54.4 million for FY2024, which is 9461.65% up from last year.
  • Corvus Pharmaceuticals' Current Assets amounted to $66.9 million in Q3 2025, which was up 5597.03% from $75.8 million recorded in Q2 2025.
  • Corvus Pharmaceuticals' Current Assets' 5-year high stood at $75.8 million during Q2 2025, with a 5-year trough of $22.9 million in Q1 2024.
  • Moreover, its 4-year median value for Current Assets was $45.5 million (2025), whereas its average is $47.3 million.
  • Its Current Assets has fluctuated over the past 5 years, first crashed by 4476.83% in 2023, then skyrocketed by 9907.66% in 2025.
  • Quarter analysis of 4 years shows Corvus Pharmaceuticals' Current Assets stood at $43.7 million in 2022, then plummeted by 35.97% to $28.0 million in 2023, then soared by 94.62% to $54.4 million in 2024, then grew by 23.04% to $66.9 million in 2025.
  • Its Current Assets was $66.9 million in Q3 2025, compared to $75.8 million in Q2 2025 and $45.5 million in Q1 2025.